Last updated on June 2018

Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma


Brief description of study

Single-agent, open-label, multi-center sequential dose escalation and expansion study of BAL101553, administered as an intravenous (IV) infusion over 48 hours to adults with advanced or recurrent solid tumors or recurrent glioblastoma.

Detailed Study Description

This is the first study of prolonged intravenous infusion of BAL101553. BAL101553 will be administered as an intravenous infusion over 48 hours, to adults with advanced or recurrent solid tumors or recurrent glioblastoma who have failed standard therapy, or for whom no effective standard therapy is available.

The primary goal of the study is to find the highest dose of BAL101553 that can safely be given to humans and to assess what side effects occur. The study will start by treating patients with a low dose. Once it has been shown that this low dose is well tolerated, new patients will be treated at higher dose levels ("dose escalation"). Once the highest, well tolerated dose is identified, 20 new patients with platinum-resistant/refractory ovarian cancer and 20 new patients with recurrent glioblastoma will be treated at that dose (this part is called "dose expansion") to further assess the tolerability and potential anticancer activity of oral BAL101553. The study will also measure pharmacokinetics, pharmacodynamic effects and assess biomarkers.

Clinical Study Identifier: NCT02895360

Contact Investigators or Research Sites near you

Start Over

Sessa, Prof

Oncology Institute of Southern Switzerland; Ospedale Regionale San Giovanni Bellinzona e Valli
Bellinzona, Switzerland
  Connect »

von Moos, PD

Cantonal Hospital of Grisons, Department of Oncology/ Haematology
Chur, Switzerland
  Connect »

Joerger, MD PhD

Cantonal Hospital of St. Gallen, Dep. Medical Oncology & Hematology
St. Gallen, Switzerland
  Connect »